The reiteration of a Buy rating and maintenance of a $4 price target by a reputable analyst like Daniil Gataulin from Chardan Capital could instill confidence among investors and potentially drive up the stock price of Adverum Biotechnologies in the short term. Analyst ratings, especially with a positive outlook, often influence investor sentiment and can lead to price movements.